Placebo + sertraline
ApprovedTerminated 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Posttraumatic Stress Disorder
Conditions
Posttraumatic Stress Disorder, Major Depressive Disorder
Trial Timeline
Sep 11, 2019 → Mar 31, 2025
NCT ID
NCT04183205About Placebo + sertraline
Placebo + sertraline is a approved stage product being developed by Johnson & Johnson for Posttraumatic Stress Disorder. The current trial status is terminated. This product is registered under clinical trial identifier NCT04183205. Target conditions include Posttraumatic Stress Disorder, Major Depressive Disorder.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04183205 | Approved | Terminated |
Competing Products
8 competing products in Posttraumatic Stress Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Duloxetine hydrochloride | Eli Lilly | Phase 3 | 77 |
| Nepicastat + Placebo | Johnson & Johnson | Phase 2 | 52 |
| Adjunctive asenapine | Merck | Approved | 85 |
| sertraline (Zoloft) | Pfizer | Pre-clinical | 22 |
| Ziprasidone | Pfizer | Approved | 84 |
| Methylphenidate Hydrochloride 20 mg + Placebo Capsule + Galantamine 12 mg | Brain Biotech | Phase 2 | 44 |
| High THC/Low CBD Cannabis + High THC/High CBD Cannabis + Low THC/Low CBD Cannabis | Tilray | Phase 2 | 47 |
| Riluzole | Brain Biotech | Phase 1 | 25 |